



BRIAN SANDOVAL
Governor

STATE OF NEVADA
DEPARTMENT OF HUMAN RESOURCES
DIVISION OF HEALTH CARE FINANCING AND POLICY
NEVADA MEDICAID
NOTICE OF OPEN PUBLIC MEETING

MICHAEL J. WILLDEN
Director

CHARLES DUARTE
Administrator

The Division of Health Care Financing and Policy (DHCFP) Pharmacy and Therapeutics Committee will conduct a public meeting on **June 23, 2011**, beginning at **1:00 p.m.** at the following location:

**Las Vegas Chamber of Commerce
6671 Las Vegas Blvd. S., Suite 300
Las Vegas, NV 89119**

Some members will be attending the meeting via video conference at Nevada State Health Division, 4150 Technology Way, Suite 300, Carson City, Nevada 89506 (public seating is limited).

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Rita Mackie at: 775-684-3681 or email rmackie@dhcfp.nv.gov in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Below is an agenda of all items scheduled to be considered. Unless otherwise noted, items may be taken out of order at the discretion of the Chairperson.

Public comment is limited to 5 minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.

AGENDA

- I. Call to Order and Roll Call
- II. *Review and Approval of the December 16, 2010 Meeting Minutes
- III. New Drug Class Reviews
 - A. Gastrointestinal Agents: Pancreatic Enzymes
 - 1. Public Comment
 - 2. Drug Class Review Presentation – Magellan Medicaid Administration
 - 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 - 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
 - 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL
- IV. Established Drug Class Reviews
 - A. Central nervous System: ADHD/Stimulants
 - 1. Public Comment
 - 2. Drug Class Review Presentation – Magellan Medicaid Administration
 - 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups

1100 E. William Street, Suite 102, Carson City, Nevada 89701
(775) 684-3600

4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

B. Gastrointestinal Agents: PPIs

1. Public Comment
2. Drug Class Review Presentation – Magellan Medicaid Administration
3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

C. Multiple Sclerosis Agents: Disease Modifying

1. Public Comment
2. Drug Class Review Presentation – Magellan Medicaid Administration
3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

D. Respiratory: Short-Acting Beta Adrenergics-Inhalers/Nebs

1. Public Comment
2. Drug Class Review Presentation – Magellan Medicaid Administration
3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

E. Skeletal Muscle Relaxants

1. Public Comment
2. Drug Class Review Presentation – Magellan Medicaid Administration
3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

V. ANNUAL REVIEW – DRUG CLASSES BEING REVIEWED DUE TO RELEASE OF NEW DRUGS

A. Analgesics: Long-Acting Narcotics

1. Public Comment
2. Drug Class Review Presentation – Magellan Medicaid Administration
3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class

- b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL
- B. Androgenic Agents: Topical
 1. Public Comment
 2. Drug Class Review Presentation – Magellan Medicaid Administration
 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL
- C. Antipsychotics: Oral, Atypical
 1. Public Comment
 2. Drug Class Review Presentation – Magellan Medicaid Administration
 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL
- D. Bone Ossification Agents: Bisphosphonates
 1. Public Comment
 2. Drug Class Review Presentation – Magellan Medicaid Administration
 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL
- E. Cardiovascular: Angiotensin II Receptor Blockers and Diuretic Combinations
 1. Public Comment
 2. Drug Class Review Presentation – Magellan Medicaid Administration
 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL
- F. Cardiovascular: Direct Renin Inhibitors and Combinations
 1. Public Comment
 2. Drug Class Review Presentation – Magellan Medicaid Administration
 3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
 4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
 5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL
- G. Diabetic Agents: Other Agents

1. Public Comment
2. Drug Class Review Presentation – Magellan Medicaid Administration
3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

H. Ophthalmic Antihistamines

1. Public Comment
2. Drug Class Review Presentation – Magellan Medicaid Administration
3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

I. Ophthalmic Non-Steroidal Anti-Inflammatory Agents

1. Public Comment
2. Drug Class Review Presentation – Magellan Medicaid Administration
3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

J. Ophthalmic Quinolones

1. Public Comment
2. Drug Class Review Presentation – Magellan Medicaid Administration
3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

K. Respiratory: Inhaled Corticosteroid/Beta-Adrenergic Combinations

1. Public Comment
2. Drug Class Review Presentation – Magellan Medicaid Administration
3. *Committee Discussion and Action
 - a. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - b. Identify Exclusions/Exceptions for Certain Patient Groups
4. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy
5. *Committee Discussion and Approval of Drugs for Inclusion on the PDL

VI. ANNUAL REVIEW – Drug Classes without Proposed Changes to the PDL

- A. Public Comment
- B. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by Magellan Medicaid Administration and the Division of Health Care Financing and Policy without Changes

1. Acne Agents: Topical, Retinoid Agents and Combinations
2. Acne Agents: Topical, Benzoyl Peroxide and Clindamycin Combinations
3. Alzheimer's Agents
4. Analgesics/Anesthetics: Topical
5. Analgesics: Tramadol and Related Drugs
6. Anaphylaxis: Self-Injectable Epinephrine
7. Antibiotics: Cephalosporins 2nd Generation
8. Antibiotics: Cephalosporins 3rd Generation
9. Antibiotics: Macrolides
10. Antibiotics: Quinolones 2nd Generation
11. Antibiotics: Quinolones 3rd Generation
12. Anticoagulants: Injectable
13. Antidepressants: Other
14. Antidepressants: SSRIs
15. Antiemetics: Oral, 5-HT₃s
16. Antifungals: Onychomycosis Agents
17. Antihistamines: 2nd Generation
18. Antihyperuricemics: Xanthine Oxidase Inhibitors for Gout
19. Anti-Migraine Agents: Triptans
20. Antiparkinson's Agents: Non-ergot Dopamine Agonists
21. Antiviral Agents: Influenza
22. Benign Prostatic Hyperplasia (BPH) Agents: Alpha-blockers
23. Benign Prostatic Hyperplasia (BPH) Agents: 5-alpha-reductase Inhibitors
24. Cardiovascular: ACE Inhibitors & Diuretic Combinations
25. Cardiovascular: Antihyperlipidemics, Bile Acid Sequestrants
26. Cardiovascular: Antihyperlipidemics, Cholesterol Absorption Inhibitors
27. Cardiovascular: Antihyperlipidemics, Statins & Statin Combinations
28. Cardiovascular: Antihyperlipidemics, Niacin Agents
29. Cardiovascular: Antihyperlipidemics, Triglyceride Lowering Agents
30. Cardiovascular: Beta Blockers
31. Cardiovascular: Calcium Channel Blockers and Combinations
32. Central Nervous System: Anticonvulsants, Barbiturates
33. Central Nervous System: Anticonvulsants, Benzodiazepines
34. Central Nervous System: Anticonvulsants, Hydantoins
35. Central Nervous System: Anticonvulsants, Miscellaneous
36. Central Nervous System: Sedative Hypnotics
37. Diabetic Agents: Biguanides
38. Diabetic Agents: Insulin Products
39. Diabetic Agents: Sulfonylureas
40. Diabetic Agents: Thiazolidinediones
41. Electrolyte Depleters
42. Erythropoiesis Stimulating Proteins
43. Fibromyalgia Agents
44. Gastrointestinal Agents: H₂Ras
45. Gastrointestinal Agents: Ulcerative Colitis
46. Growth Hormone Agents
47. Hepatitis C Agents
48. Herpetic Antiviral Agents
49. Herpetic Antiviral Agents : Topical
50. Immunomodulators: Injectable
51. Immunomodulators: Topical
52. Impetigo Agents: Topical
53. Leukotriene Modifiers
54. Multiple Sclerosis Agents: Specific Symptomatic Treatment
55. Nasal Calcitonins
56. Ophthalmic Antibiotics: Macrolides
57. Ophthalmic Glaucoma Agents
58. Otic Fluoroquinolones
59. Platelet Aggregation Inhibitors
60. Progestins for Cachexia
61. Psoriasis Agents: Topical
62. Pulmonary Arterial Hypertension Agents: Inhaled Agents

- 63. Pulmonary Arterial Hypertension Agents: Oral Agents
- 64. Respiratory: Inhaled Anticholinergic Agents
- 65. Respiratory: Inhaled Corticosteroids/Nebs
- 66. Respiratory: Intranasal Rhinitis Agents
- 67. Respiratory: Long-Acting Beta Adrenergics
- 68. Urinary Tract Antispasmodics

- C. *Committee Discussion and Approval of Drug Classes without changes for the PDL
- VII. Report by FHSC on New Drugs to Market, New Generic Drugs to Market, and New Line Extensions
- VIII. Review of Next Meeting Location, Date, and Time
- IX. Public Comment
- X. *Adjournment

***Denotes items, including subparts, on which an action may be taken.**

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site (dhcftp.state.nv.us).

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.

Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.